Brokerage firm Bank of America Downgrades its rating on C R Bard Inc(NYSE:BCR). The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by Bank of America was issued on Jul 8, 2016.
In a different note, On May 24, 2016, Barclays said it Maintains its rating on C R Bard Inc. In the research note, the firm Raises the price-target to $212.00 per share. The shares have been rated ‘Equalweight’ by the firm.
C R Bard Inc (BCR) shares turned negative on Wednesdays trading session with the shares closing down -0.79 points or -0.34% at a volume of 5,61,908. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $236.4. The peak price level was also seen at $236.4 while the days lowest was $233.5. Finally the shares closed at $234.78. The 52-week high of the shares is $239.4299 while the 52-week low is $172.21. According to the latest information available, the market cap of the company is $17,214 M.
C R Bard Inc(BCR) last announced its earnings results on Apr 27, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $873.50M. Analysts had an estimated revenue of $846.10M. Earnings per share were $2.34. Analysts had estimated an EPS of $2.17.
Several Insider Transactions has been reported to the SEC. On Jun 1, 2016, Christopher S Holland (Senior Vice President and CFO) sold 3,970 shares at $219.88 per share price.Also, On May 18, 2016, John P Groetelaars (Group President) sold 1,162 shares at $219.88 per share price.On May 16, 2016, Tommy G Thompson (director) sold 500 shares at $219.52 per share price, according to the Form-4 filing with the securities and exchange commission.
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.